We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

2.
Figure 4

Figure 4. From: The Effects of Extended Pre-Quit Varenicline Treatment on Smoking Behavior and Short-Term Abstinence: A Randomized Clinical Trial.

CO-verified 4-week continuous abstinence (not even a puff during the final four weeks of treatment; post-quit weeks 8 through 11) for all Run-in Group × Sex conditions.
Note. * p = 0.05.

Larry W. Hawk, et al. Clin Pharmacol Ther. ;91(2):172-180.
3.
Figure 3

Figure 3. From: The Effects of Extended Pre-Quit Varenicline Treatment on Smoking Behavior and Short-Term Abstinence: A Randomized Clinical Trial.

Unadjusted means (SE) for single CEQ item “Did it taste good?” (panel a) and CEQ rush scale (panel b) in reference to the first cigarette of the day by Run-in Group during the five-week pre-quit period. Note. Shaded region reflects the 3-week drug manipulation phase. Baseline (week 1) was used as a covariate in repeated measures ANOVA.

Larry W. Hawk, et al. Clin Pharmacol Ther. ;91(2):172-180.
4.
Figure 2

Figure 2. From: The Effects of Extended Pre-Quit Varenicline Treatment on Smoking Behavior and Short-Term Abstinence: A Randomized Clinical Trial.

(a) Unadjusted mean and standard error (SE) cigarettes per day for all Run-in Group × Sex conditions during the five-week pre-quit period. Note. Shaded region reflects the 3-week drug manipulation phase. Baseline (week 1) was used as a covariate in repeated measures ANOVA. (b) Mean (SE) percent reduction in CPD during the pre-quit phase (Final Week Pre-TQD; Week 5 vs. Baseline Week; Week 1) in all Run-in Group × Sex conditions, (c) Mean (SE) expired-air CO measurements for all Run-in Group × Sex conditions during the five-week pre-quit period. Analyses included Baseline (end of week 1) and Drug Manipulation Phase (end of weeks 2 and 4). During the 3-week Drug Manipulation Phase, the Extended Run-in Group received varenicline, while the Standard Run-in Group received placebo, (d) Mean (SE) percent reduction in CO during the pre-quit phase (end of week 4 vs. end of week 1) in all Run-in Group × Sex conditions.

Larry W. Hawk, et al. Clin Pharmacol Ther. ;91(2):172-180.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk